A UK study has released further evidence of an increased risk of breast cancer associated with the use of hormone replacement therapy (HRT), with the levels of risk varying among HRT types and becoming higher for combined treatments and longer duration of use.
A faecal immunochemical test (FIT) is able to accurately rule out colorectal cancer (CRC) and is as sensitive as colonoscopy, the current gold standard for CRC diagnosis, the NICE* FIT study has shown.
The initial progression-free survival (PFS) improvement obtained with the addition of olaparib to bevacizumab was sustained beyond first progression, as reflected by the significant PFS2 benefit in women with newly diagnosed, advanced high‐grade ovarian cancer, according to the final PFS2 analysis of the phase III PAOLA-1*/ENGOT-ov25 trial.
The addition of pertuzumab to standard perioperative chemotherapy (CT) comprising FLOT* and trastuzumab led to a significant improvement in pathologic complete response (pCR) in patients with HER2+ resectable oesophagogastric adenocarcinoma – at the expense however of higher toxicity rates, results of the phase II/III PETRARCA/FLOT 6 trial have shown.
In the prespecified, event-driven final analysis of the phase III SPARTAN* trial, adding the androgen receptor inhibitor (ARi) apalutamide to androgen deprivation therapy (ADT) significantly improved overall survival (OS) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Adding nivolumab to chemotherapy in the first-line setting significantly improves survival compared with chemotherapy alone in patients with HER2-negative advanced gastric/gastroesophageal (G/GEJ) cancer or oesophageal adenocarcinoma (EAC), shows the CheckMate 649 study presented at ESMO 2020.
Quadrivalent human papillomavirus (HPV) vaccination can substantially reduce the risk of invasive cervical cancer, by up to almost 90 percent in women who were vaccinated early, a large Swedish registry-based study has shown.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).